• Publications
  • Influence
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
BACKGROUND It is unknown whether either the angiotensin-II-receptor blocker irbesartan or the calcium-channel blocker amlodipine slows the progression of nephropathy in patients with type 2 diabetesExpand
  • 5,126
  • 158
  • PDF
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
BACKGROUND It is unknown whether either the angiotensin-II-receptor blocker irbesartan or the calcium-channel blocker amlodipine slows the progression of nephropathy in patients with type 2 diabetesExpand
  • 1,794
  • 154
Association of a human G-protein β3 subunit variant with hypertension
Hypertension is a common disorder of multifactorial origin that constitutes a major risk factor for cardiovascular events such as stroke and myocardial infarction. Previous studies demonstrated anExpand
  • 761
  • 59
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
Background Statins reduce the incidence of cardiovascular events in persons with type 2 diabetes mellitus. However, the benefit of statins in such patients receiving hemodialysis, who are at highExpand
  • 1,611
  • 33
End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions.
The incidence of patients with end-stage renal failure and diabetes mellitus type 2 as a comorbid condition has increased progressively in the past decades, first in the United States and Japan, butExpand
  • 734
  • 27
Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study.
It has not been firmly established whether disturbed calcium-phosphate metabolism affects progression of chronic kidney disease (CKD) in humans. In this cohort study of 227 nondiabetic patients withExpand
  • 592
  • 23
  • PDF
Nephropathy in patients with type 2 diabetes mellitus.
  • E. Ritz, S. Orth
  • Medicine
  • The New England journal of medicine
  • 7 October 1999
In the not-so-distant past, type 2 diabetes mellitus was thought to be a relatively benign condition, at least in the elderly, with relatively little effect on life expectancy or renal function.1 ItExpand
  • 725
  • 22
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
BACKGROUND Statins reduce the incidence of cardiovascular events in persons with type 2 diabetes mellitus. However, the benefit of statins in such patients receiving hemodialysis, who are at highExpand
  • 782
  • 22
  • PDF
Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.
BACKGROUND Microalbuminuria is an early predictor of diabetic nephropathy and premature cardiovascular disease. We investigated whether treatment with an angiotensin-receptor blocker (ARB) wouldExpand
  • 632
  • 19
  • PDF
Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications.
It is no a secret that we are confronted by an alarmingly increasing number of patients with progressive renal disease. There is ample evidence for the notion that angiotensin II (Ang II) is a majorExpand
  • 284
  • 19